Page last updated: 2024-08-24

capecitabine and Pancreatic Neoplasms

capecitabine has been researched along with Pancreatic Neoplasms in 327 studies

Research

Studies (327)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (0.31)18.2507
2000's92 (28.13)29.6817
2010's191 (58.41)24.3611
2020's43 (13.15)2.80

Authors

AuthorsStudies
Halfdanarson, TR; Kommalapati, A; Sonbol, MB; Starr, JS; Tella, SH1
Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW1
Hao, S; Li, S; Liu, Z; Lu, W; Ouyang, G; Pan, G; Wu, Y1
Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G1
Alwaseem, H; Bahr, A; de Stanchina, E; Fanchon, L; Humm, JL; Molina, H; O'Donoghue, I; Pillarsetty, N; Russell, J1
Balachander, A; Biswas, SK; Chen, S; Choo, SP; Chowbay, B; Guo, YA; Lam, J; Lee, B; Lee, SS; Leong, WF; Lim, TKH; Ng, M; Ong, WS; Seet, A; Skanderup, AJ; Sutiman, N; Tai, D; Yeong, J1
Aliru, M; Bagereka, P; Bhosale, P; Crane, CH; Das, P; Holliday, EB; Ikoma, N; Jacobson, G; Javle, M; Katz, MH; Kim, M; Koay, EJ; Koong, AC; Krishnan, S; Lee, JE; Ludmir, EB; Minsky, BD; Overman, M; Pant, S; Rodriguez, MJ; Smith, GL; Tamm, E; Taniguchi, CM; Tzeng, CW; Van Wieren, A; Varadhachary, G; Wang, H; Wang, X; Wolff, RA; Zaid, M1
Çakan Demirel, B; Çakıroğlu, U; Değirmencioğlu, S; Demiray, A; Demiray, AG; Doğan, T; Gököz Doğu, G; Karan, C; Özdemir, M; Özhan, N; Yapar Taşköylü, B; Yaren, A1
Deva, S; Findlay, M; Hitchen, N; Lawrence, B; Waldron, NR1
Nishimoto, A1
Li, H; Lu, J; Ma, X; Ruan, Y; Wang, L; Wu, X; Xu, H; Xu, X; Zhou, S; Zhou, X1
Dasari, A; Deming, D; George, TJ; Kopetz, S; Lieu, CH; Lin, Y; Lucas, PC; Sahin, IH; Yothers, G1
Chun, JW; Douangprachanh, S; Han, N; Han, SS; Jang, HY; Joo, HJ; Kim, TH; Koh, YH; Lee, WJ; Park, HM; Park, SJ; Woo, SM1
Agarwal, P; Bever, K; Christenson, ES; De Jesus-Acosta, A; Durham, J; Laheru, D; Le, DT; Lim, SJ; Ryan, A; Scharpf, RB; Wang, H1
Chatterjee, D; Itani, M; Navale, P; Trikalinos, NA1
Baker, KK; Chiorean, EG; Coveler, AL; Hannan, LM; King, GG; Koh, WJ; Mann, GN; Park, JO; Pillarisetty, VG; Redman, MW; Sham, JG; Swanson, PE; Whiting, SH; Zhen, DB1
Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H1
Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N1
Huang, GC; Ji, XQ; Jiang, CC; Li, AM; Li, B; Shen, ZT; Yuan, X; Zhou, H; Zhu, XX1
Baek, J; Lee, J; Ra, H1
Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L1
Berry, S; Chan, KKW; Chaves-Porras, J; Doherty, M; Ko, YJ; Parmar, A; Perry, K; Rahmadian, AP; Saluja, R; Santos, SD1
Abdel-Misih, S; Cloyd, JM; Dillhoff, ME; Dua, M; Konda, B; Norton, JA; Pawlik, TM; Poultsides, G; Schmidt, CR; Shah, MH; Squires, MH; Visser, BC; Worth, PJ1
Couto, J; Marques, B; Martins, RG; Monteiro, AR; Ribeiro, J; Rodrigues, F1
Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH1
Ueno, M1
Bodea, R; Mercea, V; Nemes, A; Vidra, R1
Bachet, JB; Mas, L; Schwarz, L1
Li, PC; Lin, GH; Wang, BC; Xiao, BY1
Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J1
Khan, GN; Patil, NR1
Antonuzzo, L; Barberis, M; Campana, D; Faviana, P; Fazio, N; Fumagalli, C; Gelsomino, F; Maisonneuve, P; Marconcini, R; Messerini, L; Puliafito, I; Rossi, G; Spada, F1
Abbott, D; Bassetti, MF; Cho, SY; Deming, D; Kuczmarska-Haas, A; LoConte, N; Lubner, M; Lubner, SJ; Minter, R; Mohindra, P; Mulkerin, DL; Reeder, SB; Ritter, MA; Ronnekleiv-Kelly, S; Uboha, NV; Weber, S; Witt, JS1
Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V1
Abraham, AG; Cox, CM; Hughes, DLI; Hurt, CN; Jones, CM; Maughan, T; Mukherjee, S; O'Neill, EE; Owens, R; Parkes, EE; Sabbagh, A; Wilhelm-Benartzi, CS; Willenbrock, F1
Al-Toubah, T; Morse, B; Pelle, E; Strosberg, J1
Bodei, L; Bongiovanni, A; Caroli, P; Cittanti, C; Di Iorio, V; Diano, D; Grana, CM; Grassi, I; Ibrahim, T; Monti, M; Nicolini, S; Paganelli, G; Pieri, F; Sansovini, M; Sarnelli, A; Severi, S1
Carrato, A; Feliu, J; Garcia-Carbonero, R; Gómez-España, MA; Martín, AM; Maurel, J; Mercadé, TM; Montes, AF; Pazo-Cid, R; Vera, R1
Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D1
Claringbold, PG; Grover, P; Kesavan, M; Lam, WS; Turner, JH1
Armesto González, EM; Cano Calderero, FX; Cerrella Cano, C; Junquera Alonso, E; Seoane Blanco, L; Terroba Alonso, M1
Colao, A; Faggiano, A; Ferraù, F; Lania, A; Modica, R; Rubino, M1
Al-Toubah, T; Haider, M; Pelle, E; Strosberg, JR; Valone, T1
Dong, J; Gao, H; Li, H; Liu, L; Ni, Q; Wang, W; Xu, H; Ye, L; Zhang, W1
Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK1
Berlin, J; Engebretson, A; Hong, TS; Katz, MHG; Khorana, AA; Maitra, A; Mangu, PB; Mohile, SG; Mumber, M; Schulick, R; Shapiro, M; Urba, S; Zeh, HJ1
Baechmann, S; Boeck, S; Clemens, MR; Esposito, I; Haas, M; Heinemann, V; Jung, A; Kettner, E; Kirchner, T; Kruger, S; Laubender, RP; Ormanns, S; Quietzsch, D; Remold, A; Schlitter, AM; Siveke, JT; Wenzel, P; Westphalen, CB1
Büchler, MW; Strobel, O2
Carilli, A; Pellini Ferreira, B; Vasquez, J1
Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z1
Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M1
Sohal, DPS1
Dueland, S; Grønbech, JE; Hoem, D; Labori, KJ; Lassen, K; Mortensen, K; Smaaland, R; Sorbye, H; Søreide, JA; Verbeke, C1
Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J1
Buchner, P; Czejka, M; Dittrich, C; Gruber, A; Kirchbaumer Baroian, N; Kitzmueller, M; Sahmanovic Hrgovcic, A1
Koh, H; Masai, N; Oh, R; Tatsumi, D; Uemoto, K; Yamada, K; Yamazaki, M; Yasumoto, T1
Bendell, J; Clark, J; Dawkins, F; Greeno, E; Hidalgo, M; Hurwitz, H; Li, CP; Macarulla, T; O'Reilly, EM; Sahai, V; Salvo, MG; Sama, A; Van Cutsem, E; Verslype, C; Walker, C; Yu, KH1
Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A1
Klimstra, DS; Laino, ME; Mannelli, L; Ragucci, M1
Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E1
Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M1
Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P1
Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S1
Borbath, I; Conroy, T; Malka, D1
Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ1
Amoroso, V; Berruti, A; Bertani, E; Cella, CA; Fazio, N; Laffi, A; Maisonneuve, P; Pellicori, S; Pozzari, M; Spada, F1
Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H1
Byrne, MM; Godara, A; Saif, MW; Siddiqui, NS1
Bridgewater, J; Corrie, PG; Hawkins, M; Hurt, CN; Maughan, T; Mukherjee, S; O'Neill, E; Parsons, P; Patel, N; Radhakrishna, G; Sebag-Montefiore, D; Shaw, R; Strauss, VY; Tranter, B; Virdee, PS; Ward, E1
Brixi, H; Cadiot, G; Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Legoux, JL; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T1
Conroy, T; Van Laethem, JL1
Cros, J; de Boissieu, P; de Mestier, L; Evrard, C; Hammel, P; Hentic, O; Lombard-Bohas, C; Rebours, V; Ruszniewski, P; Tougeron, D; Walter, T1
Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y1
Kaiho, T; Kataoka, M; Kobayashi, S; Machida, T; Nakadai, E; Nishimura, M; Oka, Y; Okaniwa, A; Suda, R; Yamada, H; Yanagisawa, S1
Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA1
Chau, I; Cunningham, D; Hubner, RA; Worsnop, F1
Büchler, MW; Combs, SE; Diener, MK1
Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H1
Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C1
Costa, FP; Gumz, B; Pasche, B1
Ng, J; Ove, R; Russo, S; Saif, MW1
Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L1
Han, SS; Kim, BH; Kim, DY; Kim, JY; Kim, SS; Kim, TH; Kim, YJ; Koh, YH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM1
Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA1
Huber, KE; Saif, MW; Savir, G1
Li, CH; Ma, TH; Shi, SB; Tang, XY1
Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Rodriguez, T; Saif, MW1
Ilyas, S; Saif, MW; Wasif, K1
Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH1
Bahary, N; Brand, R; Burton, SA; Heron, DE; Krasinskas, AM; Lembersky, B; Moser, AJ; Quinn, AE; Rajagopalan, MS; Wegner, RE; Zeh, HJ1
Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY1
Balzano, G; Bettinardi, V; Calandrino, R; Castoldi, R; Cattaneo, GM; Cereda, S; Di Muzio, N; Gianolli, L; Gusmini, S; Longobardi, B; Passoni, P; Reni, M; Slim, N; Staudacher, C1
Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN1
Annels, NE; Billingham, L; Corrie, P; Cunningham, D; Eatock, M; Gabitass, RF; Middleton, G; Neoptolemos, JP; Pandha, H; Shaw, VE; Smith, D; Valle, J; Wadsley, J1
Bussom, S; Cheng, YC; Elligers, K; Jiang, Z; Kaley, K; Lamb, L; Li, J; Liu, SH; Saif, MW1
Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L1
Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS1
Armstrong, G; Caplin, ME; Corrie, PG; Cunningham, D; Hardy, R; Lao-Sirieix, SH; Luong, TV; Meyer, T; Navalkissoor, S; Qian, W; Reed, N; Shaw, A; Talbot, DC; Valle, JW1
Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G1
Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L1
Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB1
Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J1
Becker, G; Gaertner, J1
Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W1
Cunningham, SC; Gormley, PE; Iacobuzio-Donahue, CA; Kern, SE; Patel, K1
Saif, MW; Tejani, MA2
Claringbold, PG; Kesavan, M; Turner, JH1
Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L1
Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN1
Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M1
Adams, J; Allen, JN; Ancukiewicz, M; Blaszkowsky, LS; Borger, DR; Boucher, Y; Clark, JW; DeLaney, TF; Deshpande, V; Duda, DG; Fernandez-del Castillo, C; Ferrone, CR; Grillo, T; Hong, TS; Jain, RK; Kwak, EL; Mamon, HJ; Ryan, DP; Shinagare, S; Wadlow, RC; Winrich, B; Wo, JY; Yeap, BY; Zhu, AX1
Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J1
Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J1
Cooper, A; Grey, A; Grimison, P; McNeil, C; O'Toole, S; Thompson, J1
Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J1
Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN1
Chang, BW; Johung, KL; Saif, MW1
Li, J; Saif, MW2
Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y1
Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR1
Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W1
Graziani, C; Hegde, S; Saif, MW1
Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S1
Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G1
Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A1
Addeo, P; Bachellier, P; Belletier, C; De Blasi, V; Dufour, P; Fuchshuber, P; Oussoultzoglou, E; Rosso, E; Simone, G1
Klümpen, HJ; Kordes, S; Richel, DJ; Schellens, JH; Weterman, MJ; Wilmink, JW1
André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN1
Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C1
Claringbold, PG; Turner, JH1
Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM1
El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH1
Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M1
Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS1
Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA1
Geyer, AI; Kelly, DW; O'Reilly, EM; Sahin, IH1
Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M1
Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V1
Andersson, R; Ansari, D; Kölby, D; Sasor, A; Thilén, J1
Barucca, V; D'Antonio, C; Falcone, R; Marchetti, P; Milano, A; Onesti, CE; Palombi, L; Righini, R; Roberto, M; Romiti, A1
Gabrielson, A; He, AR; Hwang, JJ; Ley, L; Marshall, JL; Pishvaian, MJ; Weiner, LM; Wu, Z; Zhuang, T1
Abrams, RA; Blazeby, JM; Bridges, S; Bridgewater, J; Crosby, T; Dutton, P; Falk, S; Griffiths, G; Hurt, CN; Johnson, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Staffurth, J1
Abrams, MJ; Chang, BW; Huber, KE; Knisely, JP; Russo, SM; Saif, MW1
Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G1
Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C1
Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V1
Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D1
Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V1
Bounthavong, M; Chen, T; Nguyen, CP; Wong, SF1
Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A1
Abramson, RG; Arlinghaus, LR; Berlin, JD; Bhaskara, S; Cardin, DB; Chakravarthy, AB; Chan, E; Goff, L; Hiebert, S; Merchant, N; Parikh, A; Yankeelov, TE1
Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP1
Chadha, AS; Chatterjee, D; Clemons, M; Crane, CH; Das, P; Delclos, ME; Fleming, JB; George, G; Gunther, JR; Javle, MM; Katz, MH; Krishnan, S; Minsky, BD; Munsell, MF; Singh, PK; Skinner, HD; Varadhachary, GR; Wang, H; Wolff, RA1
Bedossa, P; Couvelard, A; Cros, J; Gille, N; Hammel, P; Hentic, O; Lévy, P; Maire, F; Paradis, V; Rebours, V; Ruszniewski, P; Theou-Anton, N; Vernerey, D; Zappa, M1
Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S1
Huguet, F; Mornex, F; Orthuon, A1
Black, M; Brelsford, M; Cives, M; Ghayouri, M; Meeker, A; Morse, B; Rizzo, A; Strosberg, J1
Jadhav, P; Rogers, JE; Shroff, R1
Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY1
Cross, WE1
Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL1
Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A1
Saif, MW1
Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K1
Abbruzzese, JL; Blais, JC; Hess, KR; Varadhachary, GR; Wolff, RA; Xiong, HQ1
Boehm, KA; Cartwright, T; Richards, DA1
Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K1
Saif, MW; Wasif, N1
Dilulio, J; Ganju, V; Khamly, K; Leong, T; Matera, A; Michael, M; Milner, AD; Muller, A; Ngan, SY; Price, T; Strickland, AH; Zalcberg, JR1
Büchler, P; Endlicher, E; Geissler, M; Gregor, M; Harder, J; Heinemann, V; Hofheinz, R; Kanzler, S; Klöppel, G; Mihaljevic, A; Schmiegel, W; Seufferlein, T1
Gennatas, C; Gennatas, S; Michalaki, V1
Crane, CH; Evans, DB; Fleming, JB; Settle, SH; Varadhachary, G; Wolff, RA1
Foo, KF; Wang, ML1
Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I1
Harold, L; Rajebi, MR; Saif, MW; Shahrokni, A1
Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A1
Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM1
Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM1
Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T1
Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J1
Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V1
Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T1
Sherman, WH1
Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA1
Bell, D; Diasio, RB; Hashmi, S; Saif, MW1
Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C1
Choi, DW; Choi, SH; Heo, JS; Jun, HJ; Kang, WK; Kim, HS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS; Yi, SY1
Bender, GP; Masellis, AM; Sielaff, TD1
Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J1
Macarulla, T; Tabernero, J1
Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J1
Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S1
Cheng, YC; Elligers, K; Grant, N; Jiang, ZL; Lamb, L; Lansigan, F; Liu, SH; Mezes, M; Ruta, S; Saif, MW1
Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM1
Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD1
Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J1
Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD1
Mehta, SP1
Greten, TF; Manns, MP; Plentz, RR1
Caprino, P; Caravatta, L; Cellini, N; Deodato, F; Di Lullo, L; Giglio, G; Ingrosso, M; Ippolito, E; Macchia, G; Massaccesi, M; Mattiucci, GC; Mignogna, S; Morganti, AG; Picardi, V; Sofo, L; Tambaro, R; Valentini, V1
Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S1
Adams, J; Blaszkowsky, LS; DeLaney, TF; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Mamon, HJ; Mino-Kenudson, M; Ryan, DP; Winrich, B; Yeap, B1
Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L1
Chefrour, M; Ciccolini, J; Ferri-Dessens, RM; Fischel, JL; Formento, P; Francoual, M; Giacometti, S; Marouani, H; Mercier, C; Milano, G; Renée, N1
Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R1
Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P1
Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M1
Choi, H; Choi, IB; Han, CW; Jang, JW; Ji, JS; Kang, YN; Kay, CS; Kim, BW; Kim, JY; Lee, BI1
Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J1
Cameron, JL; Herman, JM; Horowitz, DP; Hsu, CC; Makary, MA; Pawlik, TM; Robinson, R; Schulick, RD; Wang, J; Winter, JM1
Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA1
Kaley, K; Penney, R; Saif, MW; Syrigos, K1
Chen, DT; Choi, J; Coppola, D; Fine, RL; Helm, J; Kvols, L; Nasir, A; Strosberg, JR1
Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N1
Bell, D; Black, G; Ferrucci, LM; Heimburger, DC; McCorkle, R; Saif, MW; Thornton, J1
Arjona-Sánchez, A; Cruz, A; Muñoz, Mdel C; Muntané, J; Padillo, FJ; Perea, MD; Ruiz-Rabelo, J; Túnez, I; Vázquez, R1
Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E1
Han, SS; Hong, EK; Kim, DY; Kim, SH; Kim, TH; Lee, WJ; Moon, SH; Park, JW; Park, SJ; Woo, SM; Yoo, T1
Arjona, A; Montilla, P; Muntané, J; Padillo, J; Perea, D; Ruiz-Rabelo, J; Túnez, I; Vázquez, R1
Adams, RB; Bauer, TW; de Lange, EE; Nolan, NJ; Rich, TA; Stelow, EB; Stokes, JB; Walters, DM; Weiss, GR1
Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J1
Belli, C; Cereda, S; Reni, M; Villa, E1
Oberstein, PE; Saif, MW1
Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY1
Adenis, A; Conroy, T; Gavoille, C1
Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T1
Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP1
Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T1
Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C1
Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS1
Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E1
Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L1
Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA1
Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N1
Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R1
Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH1
Lau, PC; Ng, WT; Yu, SC; Zheng, SF1
Broadwater, G; Clough, RW; Czito, BG; Guy, CD; Papalezova, KT; Papavassiliou, P; Tyler, DS; White, RR; Willett, CG; Zagar, TM1
Klümpen, HJ; Kordes, S; Richel, DJ; Stevens, AJ; Weterman, MJ; Wilmink, JW1
Bitzer, M; Boeck, S; Buechler, P; Endlicher, E; Geissler, M; Harder, J; Heinemann, V; Hofheinz, R; Ihorst, G; Kloeppel, G; Moehler, M; Reinacher-Schick, A; Röcken, C; Schmoor, C1
Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Deshpande, V; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Warshaw, AL; Willett, CG; Zhu, AX1
Govindarajan, R; Hung, SW; Mody, HR1
Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK1
El-Rayes, BF; Zafar, SF1
Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH1
Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C1
Saif, MW; Strimpakos, AS; Syrigos, KN1
Ramfidis, VS; Saif, MW; Strimpakos, AS; Syrigos, KN1
Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB1
Inaba, S; Koyama, H; Nakatsukasa, K; Tokugawa, T1
Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ1
Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG1
Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C1
Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Nagel, D; Stieber, P; Wittwer, C1
Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM1
Enk, AH; Gronau, M; Hassel, JC; Jäger, D1
Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J1
Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR1
Bearss, D; Von Hoff, DD1
André, T; Artru, P; Louvet, C1
Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H1
Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M1
Heinemann, V1
Chang, HM; Kang, YK; Kim, JH; Kim, JS; Kim, MH; Kim, TW; Lee, JL; Lee, SK1
Rich, TA; Shepard, R1
Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E1
Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N1
Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V1
Diasio, RB; McGee, PJ; Saif, MW; Wood, TE1
Catalano, V; Jirillo, E; Mazzone, F; Passantino, L; Patruno, R; Pellecchia, A; Penna, A; Ranieri, G; Valerio, P; Zito, AF1
Ben-Josef, E; Chang, AE; Colletti, LM; Hejna, GF; Lawrence, TS; McGinn, CJ; Normolle, DP; Schneider, BJ; Zalupski, MM1
Moody, JS; Russo, SM; Saif, MW1
Lopes, G; Rocha Lima, CM1
Alexandrescu, DT; Dutcher, JP; Wiernik, PH1
Baddi, L; Beck, AC; Blumenthal, DT; Chua-Adajar, R; Futterer, S; Gradishar, W; Raizer, JJ; Semenov, I; Simuni, T; Tellez, C; Videnovic, A1
Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA1
Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J1
Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM1
Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D1
Abbruzzese, JL; Amos, C; Charnsangavej, C; Crane, CH; Delclos, ME; Ellis, LM; Evans, DB; Ho, L; Lee, JE; Ng, C; O'Reilly, M; Pisters, PW; Tamm, EP; Wolff, RA; Xiong, HQ1
Diasio, R; Saif, MW1
Chua, YJ; Cunningham, D1
Crane, CH; Evans, DB; Pisters, PW; Varadhachary, G; Wolff, RA1
Black, G; Diasio, R; Johnson, M; Russo, S; Saif, MW1
de Jager, J; Stebbing, J1
Neoptolemos, JP; Smith, DB1
Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA1
Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H1
Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS1
Kindler, HL1
Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J1
Boige, V; Ducreux, M; Malka, D1
Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A1
Kim, R; Saif, MW1
Moore, MJ; Welch, SA1
Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Cina, S; Dietrich, D; Figer, A; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, B; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K1
Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Janjan, NA; Krishnan, S; Rana, V; Varadhachary, GR; Wolff, RA1
Choi, J; Gardner, N; Hoffe, S; Kvols, L; Strosberg, J1
Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E1
Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD1
Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E1
Albiin, N; Almström, M; Byström, P; Isaksson, B; Johnsson, A; Lind, PA; Permert, J1
Ammann, M; Duquesne, A; Fürstenberger, G; Schmid, P; Senn, HJ1
Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX1
Boeck, HP; Boeck, S; Geissler, M; Golf, A; Heinemann, V; Hochhaus, A; Hoehler, T; Kettner, E; Ko, Y; Kojouharoff, G; Lordick, F; Mahlberg, R; Neugebauer, S; Schmid, B; Schoppmeyer, K; Seipelt, G; Stauch, M; Wein, A1
Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A1
Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS1
de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M1
Bajetta, E; Bodoky, G; Dietrich, D; Figer, A; Glimelius, B; Grawe, P; Herrmann, R; Hess, V; Ruhstaller, T; Saletti, P; Scheithauer, W1
Kim, YT1
Chua, YJ; Zalcberg, JR1
Rocha-Lima, CM1
Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R1
Saadati, H; Saif, MW1
Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W1
Alschuler, L; Block, KI; Gyllenhaal, C; Kranz, S; Roddy, GD; Rubin, D1
Garcia, L; Goodwin, AL; Von Hoff, DD1
Twelves, C1
Cartwright, TH; Chen, YM; Cohn, A; Cox, JV; Schulz, JJ; Szatrowski, TP; Varkey, JA1
Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ1

Reviews

46 review(s) available for capecitabine and Pancreatic Neoplasms

ArticleYear
Management of well-differentiated neuroendocrine tumors.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:9

    Topics: Antineoplastic Agents; Capecitabine; Everolimus; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Somatostatin

2021
Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
    Medicine, 2021, Dec-03, Volume: 100, Issue:48

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome

2021
Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment.
    World journal of gastroenterology, 2022, Jul-28, Volume: 28, Issue:28

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Products; Capecitabine; Cisplatin; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitogen-Activated Protein Kinase Kinases; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras)

2022
Literature review of imaging, pathological diagnosis, and outcomes of metachronous lung and pancreatic metastasis of cecal cancer.
    World journal of surgical oncology, 2022, Oct-17, Volume: 20, Issue:1

    Topics: Aged; Capecitabine; Carcinoembryonic Antigen; Cecal Neoplasms; Colonic Neoplasms; Humans; Lung; Male; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Rectal Neoplasms

2022
Adjuvant treatment for resected pancreatic adenocarcinoma: A systematic review and network meta-analysis.
    Critical reviews in oncology/hematology, 2020, Volume: 145

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Humans; Network Meta-Analysis; Paclitaxel; Pancreatic Neoplasms

2020
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
    Current opinion in oncology, 2020, Volume: 32, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic

2020
Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
    Annals of palliative medicine, 2020, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms

2020
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Radioisotopes; Somatostatin; Temozolomide; Treatment Outcome

2021
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    PharmacoEconomics, 2018, Volume: 36, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical

2018
Chemotherapy in Pancreatic Cancer: A Systematic Review.
    Medicina (Kaunas, Lithuania), 2018, Jul-11, Volume: 54, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome

2018
Systemic therapies in patients with advanced well-differentiated pancreatic neuroendocrine tumors (PanNETs): When cytoreduction is the aim. A critical review with meta-analysis.
    Cancer treatment reviews, 2018, Volume: 71

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cytoreduction Surgical Procedures; Humans; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Sunitinib; Temozolomide; Vascular Endothelial Growth Factor A

2018
Capecitabine for the treatment of pancreatic cancer.
    Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase

2019
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.
    Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide

2012
Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms

2015
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
    Cancer control : journal of the Moffitt Cancer Center, 2008, Volume: 15, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines

2008
The role of capecitabine in the management of tumors of the digestive system.
    Reviews on recent clinical trials, 2009, Volume: 4, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A

2009
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2009, Volume: 13, Issue:2

    Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms

2009
Medical management of pancreatic adenocarcinoma.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2009, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking

2009
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
    World journal of gastroenterology, 2010, Feb-14, Volume: 16, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms

2010
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis

2010
Palliative chemotherapy for pancreatic malignancies.
    The Surgical clinics of North America, 2010, Volume: 90, Issue:2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus

2010
Molecular therapy of pancreatic cancer.
    Minerva endocrinologica, 2010, Volume: 35, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A

2010
Challenges of drug resistance in the management of pancreatic cancer.
    Expert review of anticancer therapy, 2010, Volume: 10, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment

2010
Metastatic pancreatic cancer: old drugs, new paradigms.
    Current opinion in oncology, 2011, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines

2011
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
    Journal of digestive diseases, 2012, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy

2012
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
    Cancer letters, 2012, Jul-28, Volume: 320, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Signal Transduction

2012
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    American journal of clinical oncology, 2014, Volume: 37, Issue:2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines

2014
New drugs for patients with pancreatic cancer.
    Current opinion in oncology, 2002, Volume: 14, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Capecitabine; Deoxycytidine; Diphtheria Toxoid; Fluorouracil; Gastrins; History, 16th Century; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic

2002
[Gemcitabine-based combinations in inoperable pancreatic cancers].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome

2002
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids

2002
COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas.
    American journal of clinical oncology, 2003, Volume: 26, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Esophageal Neoplasms; Fluorouracil; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Stomach Neoplasms; Sulfonamides

2003
[The update on pancreatic cancer chemotherapy].
    Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:10

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors

2003
Docetaxel in the management of advanced pancreatic cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 4

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide

2005
Chemotherapy for advanced pancreatic cancer.
    Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors

2006
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
    Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Radiotherapy Dosage

2006
Capecitabine in carcinoma of the pancreas.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis

2006
Pancreatic cancer: an update.
    Current oncology reports, 2007, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines

2007
Treatment of advanced pancreatic cancer.
    Seminars in oncology, 2007, Volume: 34, Issue:2 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate

2007
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
    JOP : Journal of the pancreas, 2007, May-09, Volume: 8, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur

2007
[Treatments of pancreatic cancer from the standpoint of medical oncology].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur

2007
Safety of capecitabine use in patients with liver dysfunction.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:9

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms

2007
[Chemotherapy for pancreatic cancer].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2008, Volume: 51, Issue:2

    Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines

2008
Pancreatic cancer--is the wall crumbling?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis

2008
New directions in the management of advanced pancreatic cancer: a review.
    Anti-cancer drugs, 2008, Volume: 19, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines

2008
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
    British journal of cancer, 1998, Volume: 78 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed

1998
Vision of the future: capecitabine.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Kidney Neoplasms; Male; Ovarian Neoplasms; Pancreatic Neoplasms

2001

Trials

111 trial(s) available for capecitabine and Pancreatic Neoplasms

ArticleYear
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
    International journal of cancer, 2022, 08-01, Volume: 151, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorouracil; Humans; Immunity; Irinotecan; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome

2022
Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation.
    International journal of radiation oncology, biology, physics, 2022, 11-01, Volume: 114, Issue:3

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms

2022
Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US.
    Oncology (Williston Park, N.Y.), 2022, 10-07, Volume: 36, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Circulating Tumor DNA; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies

2022
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
    JAMA surgery, 2019, 11-01, Volume: 154, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome

2019
A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer.
    International journal of radiation oncology, biology, physics, 2021, 02-01, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Capecitabine; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Treatment Outcome

2021
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
    British journal of cancer, 2021, Volume: 124, Issue:3

    Topics: Aged; Biomarkers, Tumor; Capecitabine; Chemokine CCL5; Chemoradiotherapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Regression Analysis; ROC Curve; Treatment Outcome

2021
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 48, Issue:10

    Topics: Capecitabine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies

2021
Long-term hematologic toxicity of 177Lu-octreotate-capecitabine-temozolomide therapy of GEPNET.
    Endocrine-related cancer, 2021, 06-20, Volume: 28, Issue:7

    Topics: Capecitabine; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Temozolomide; Treatment Outcome

2021
Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.
    BMC surgery, 2017, Aug-25, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms

2017
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
    Investigational new drugs, 2018, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease Progression; Disease-Free Survival; Female; Humans; Janus Kinase 1; Janus Kinase 2; Male; Middle Aged; Nitriles; Pancreatic Neoplasms; Pyrazoles; Pyrimidines

2018
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 102

    Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult

2018
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
    American journal of clinical oncology, 2019, Volume: 42, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution

2019
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
    BMC cancer, 2019, Feb-04, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nelfinavir; Neoplasms, Second Primary; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Treatment Outcome; Young Adult

2019
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome

2013
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
    British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8

    Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate

2013
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2013, Jul-15, Volume: 86, Issue:4

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated

2013
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Thalidomide

2013
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 110, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Radiation; Female; Fluorouracil; Humans; Intraoperative Complications; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Photons; Prospective Studies; Radiation Injuries

2014
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    International journal of radiation oncology, biology, physics, 2013, Dec-01, Volume: 87, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Blood Vessels; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Duodenum; Feasibility Studies; Female; Fluorouracil; Gastric Mucosa; Humans; Induction Chemotherapy; Intestinal Mucosa; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Tumor Burden

2013
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drugs, Chinese Herbal; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome

2014
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Streptozocin; Surveys and Questionnaires; Treatment Outcome

2014
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids

2014
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2014, Mar-15, Volume: 88, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated

2014
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome

2014
Clinical benefit response in pancreatic cancer trials revisited.
    Oncology research and treatment, 2014, Volume: 37, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome

2014
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Neuroendocrinology, 2014, Volume: 99, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome

2014
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Fatigue; Female; Fluorouracil; Half-Life; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Prodrugs; Severity of Illness Index; Survival Analysis

2014
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11

    Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult

2014
A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2014, Jul-15, Volume: 89, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Genes, ras; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Proton Therapy; ras Proteins; Receptors, CXCR

2014
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphopenia; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Quinazolines; Radiography; Severity of Illness Index; Survival Analysis; Tumor Burden

2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase

2014
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
    Cancer, 2015, Mar-01, Volume: 121, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome

2015
Oxaliplatin and ototoxicity: is it really safe for hearing?
    Turkish journal of medical sciences, 2014, Volume: 44, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Hearing Loss; Hearing Tests; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms

2014
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms

2015
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases

2015
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome

2015
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
    Neuroendocrinology, 2016, Volume: 103, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Temozolomide; Tomography Scanners, X-Ray Computed; Treatment Outcome

2016
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib

2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-01, Volume: 33, Issue:34

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate

2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult

2015
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Mar-01, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome

2016
Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome

2015
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
    International journal of radiation oncology, biology, physics, 2015, Nov-15, Volume: 93, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Fatigue; Feeding and Eating Disorders; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Health Status; Humans; Induction Chemotherapy; Male; Pancreatic Neoplasms; Quality of Life; Statistics, Nonparametric; Surveys and Questionnaires; United Kingdom

2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Investigational new drugs, 2016, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome

2016
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
    Oncotarget, 2016, Mar-15, Volume: 7, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil

2016
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
    British journal of cancer, 2016, Mar-01, Volume: 114, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase

2016
Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 119, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Diffusion Magnetic Resonance Imaging; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms

2016
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.
    JAMA surgery, 2016, 08-17, Volume: 151, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate

2016
Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiation Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Repressor Proteins; Treatment Outcome

2016
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
    British journal of cancer, 2016, Jul-26, Volume: 115, Issue:3

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis

2016
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
    Medicine, 2017, Volume: 96, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate

2017
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms

2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure

2008
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.
    Cancer, 2008, Oct-15, Volume: 113, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Oxaloacetates; Pancreatic Neoplasms; Survival Analysis

2008
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
    British journal of cancer, 2009, Jan-13, Volume: 100, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms

2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Oncology, 2009, Volume: 76, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Carcinoma, Pancreatic Ductal; Celecoxib; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Pyrazoles; Sulfonamides

2009
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome

2009
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
    Anticancer research, 2009, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms

2009
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
    British journal of cancer, 2009, Jun-16, Volume: 100, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome

2009
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
    Pancreas, 2009, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms

2009
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-01, Volume: 27, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome

2009
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
    Anti-cancer drugs, 2010, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines

2010
Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer.
    Anti-cancer drugs, 2010, Volume: 21, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Radiotherapy Dosage

2010
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom

2009
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome

2009
Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2010, Volume: 17, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Fluorouracil; Glycyrrhiza; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paeonia; Pancreatic Neoplasms; Phytotherapy; Scutellaria baicalensis; Ziziphus

2010
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Taxoids; Treatment Outcome

2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demography; Deoxycytidine; Enhancer Elements, Genetic; Female; Fluorouracil; Gemcitabine; Genotype; Homozygote; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Survival Analysis; Thymidylate Synthase; Treatment Outcome

2011
Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome

2010
Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head.
    International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1

    Topics: Aged; Aged, 80 and over; Capecitabine; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Cytarabine; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Humans; Length of Stay; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prescriptions; Prospective Studies; Proton Therapy; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted

2011
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids; Treatment Outcome

2011
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome

2010
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 95, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Compliance; Treatment Outcome

2010
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids

2011
Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer.
    Radiation oncology (London, England), 2010, Jun-28, Volume: 5

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated

2010
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:11

    Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Linear Models; Male; Middle Aged; Nutritional Status; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2011
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome

2012
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein

2012
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    American journal of clinical oncology, 2012, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome

2012
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
    Pancreas, 2011, Volume: 40, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure

2011
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult

2012
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    American journal of clinical oncology, 2012, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome

2012
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome

2012
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome

2012
A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced pancreatic cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sirolimus; Treatment Outcome

2013
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gene Expression; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2012
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome

2012
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Surgery, 2012, Volume: 152, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea

2012
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
    Gut, 2013, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome

2013
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome

2012
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome

2012
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
    British journal of cancer, 2013, Feb-05, Volume: 108, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins

2013
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
    Chemotherapy, 2012, Volume: 58, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting

2012
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin

2013
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
    Anticancer research, 2013, Volume: 33, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines

2013
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome

2003
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-01, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Switzerland

2003
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain

2004
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Statistics as Topic; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome; Tumor Necrosis Factor-alpha

2005
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms

2006
Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-01, Volume: 24, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peptic Ulcer Hemorrhage; Radiotherapy, Adjuvant; Treatment Outcome

2006
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis

2007
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Oncology research, 2006, Volume: 16, Issue:6

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome

2006
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms

2007
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome

2008
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome

2008
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis

2008
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate

2007
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
    British journal of cancer, 1998, Volume: 78 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed

1998
Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-01, Volume: 20, Issue:1

    Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Consumer Product Safety; Deoxycytidine; Female; Fluorouracil; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Survival Analysis

2002
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome

2002

Other Studies

171 other study(ies) available for capecitabine and Pancreatic Neoplasms

ArticleYear
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
    International journal of cancer, 2022, 05-15, Volume: 150, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms

2022
Capecitabine as a Second-line Treatment for Older Patients with Pancreatic Cancer.
    Current pharmaceutical biotechnology, 2022, Volume: 23, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Pancreatic Neoplasms; Treatment Outcome

2022
Analysis of capecitabine metabolites in conjunction with digital autoradiography in a murine model of pancreatic cancer suggests extensive drug penetration through the tumor.
    Pharmacology research & perspectives, 2022, Volume: 10, Issue:2

    Topics: Animals; Autoradiography; Capecitabine; Disease Models, Animal; Humans; Mice; Pancreatic Neoplasms; Prodrugs

2022
Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; DNA, Complementary; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Messenger

2022
Real-world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Febrile Neutropenia; Gemcitabine; Humans; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome

2023
Capecitabine and temozolomide for metastatic intermediate to high-grade pancreatic neuroendocrine neoplasm: a single center experience.
    The Korean journal of internal medicine, 2022, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome

2022
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma.
    Cancer research communications, 2022, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Cell-Free Nucleic Acids; Cisplatin; Deoxycytidine; Humans; Irinotecan; Pancreatic Neoplasms; Pilot Projects; Proto-Oncogene Proteins p21(ras)

2022
Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associations.
    Virchows Archiv : an international journal of pathology, 2023, Volume: 483, Issue:2

    Topics: Adult; Aged; Capecitabine; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tuberous Sclerosis

2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Pancreas, 2023, May-01, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms

2023
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    BMC cancer, 2019, Oct-22, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Radiosurgery; Treatment Outcome

2019
Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiosurgery; Retrospective Studies

2020
Ultra-widefield angiographic imaging of albumin-bound paclitaxel-induced cystoid macular edema.
    Indian journal of ophthalmology, 2019, Volume: 67, Issue:12

    Topics: Adult; Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Coloring Agents; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Macular Edema; Oxaliplatin; Pancreatic Neoplasms; Tomography, Optical Coherence

2019
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:5

    Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies

2020
Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
    Pancreas, 2020, Volume: 49, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Registries; Retrospective Studies; Temozolomide; Time Factors; United States

2020
Metastatic VIPoma, Cosecreting Insulin, With Complete Response to Lanreotide, Capecitabine, and Temozolomide.
    Pancreas, 2020, Volume: 49, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Insulin; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peptides, Cyclic; Remission Induction; Secretory Pathway; Somatostatin; Temozolomide; Treatment Outcome; Vipoma

2020
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms

2020
[The Current and Future Status of Perioperative Therapy in Pancreatic Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:4

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Japan; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms

2020
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
    Journal of gastrointestinal and liver diseases : JGLD, 2020, 06-04, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2

2020
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome

2020
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
    The American journal of case reports, 2020, Jul-13, Volume: 21

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms, Hereditary Nonpolyposis; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Oxaliplatin; Pancreatic Neoplasms

2020
Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis.
    Endocrine, 2021, Volume: 72, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Italy; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies; Temozolomide; Treatment Outcome

2021
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
    Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate

2021
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
    The oncologist, 2021, Volume: 26, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Leucovorin; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome

2021
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:5

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Irinotecan; Leucovorin; Medical Oncology; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Quality of Life; Societies, Medical; Spain

2021
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors

2021
Capecitabine-induced hyperammonemic encephalopathy.
    Revista espanola de enfermedades digestivas, 2022, Volume: 114, Issue:1

    Topics: Adenocarcinoma; Aged; Ammonia; Brain Diseases; Capecitabine; Humans; Hyperammonemia; Male; Pancreatic Neoplasms

2022
Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2021, 08-24, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Treatment Outcome

2021
Sequential Capecitabine/Temozolomide and Sunitinib Treatment in Patients With Metastatic Well-Differentiated Grade 1/Grade 2 Pancreatic Neuroendocrine Tumors.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2022, Volume: 28, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Sunitinib; Temozolomide

2022
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
    Molecular cancer research : MCR, 2017, Volume: 15, Issue:8

    Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays

2017
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms

2017
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
    British journal of cancer, 2017, May-23, Volume: 116, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Survival Rate

2017
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2017, Volume: 88, Issue:6

    Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care

2017
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
    The American journal of the medical sciences, 2017, Volume: 353, Issue:6

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Carcinoma, Hepatocellular; Dacarbazine; Glucagon; Glucagonoma; Humans; Jaundice; Liver; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Temozolomide; Treatment Outcome

2017
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia

2017
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate

2017
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
    Chinese clinical oncology, 2017, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant

2017
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
    Gut and liver, 2018, May-15, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil

2018
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Computer Simulation; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Models, Biological; Pancreatic Neoplasms; Prognosis; Tissue Distribution

2018
[Radiofrequency Ablation under Computed Tomography during Arterial Portography for Hypovascular Liver Metastases from Advanced Pancreatic Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:2

    Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheter Ablation; Combined Modality Therapy; Humans; Liver Neoplasms; Male; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed

2018
Hepatobiliary and Pancreatic: Primary acinar cell carcinoma of the liver showing good response to chemotherapy.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:5

    Topics: Acinar Cells; Antineoplastic Agents; Biopsy; Capecitabine; Carcinoma, Acinar Cell; Diagnosis, Differential; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography

2018
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
    American journal of clinical oncology, 2018, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure

2018
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
    PharmacoEconomics, 2018, Volume: 36, Issue:11

    Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom

2018
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    The British journal of radiology, 2018, Volume: 91, Issue:1091

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution

2018
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:10

    Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms

2018
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019, Volume: 90, Issue:Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care

2019
Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
    Neuroendocrinology, 2019, Volume: 108, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Digestive System Neoplasms; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Propensity Score; Temozolomide

2019
Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?
    The Lancet. Oncology, 2019, Volume: 20, Issue:3

    Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms

2019
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor.
    Neuroendocrinology, 2020, Volume: 110, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide

2020
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
    Minerva chirurgica, 2020, Volume: 75, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome

2020
[A Case of Pancreatic Metastasis from Colon Cancer Successfully Treated with Capecitabine/Oxaliplatin plus Bevacizumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms

2019
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
    Pancreas, 2019, Volume: 48, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome

2019
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
    Pancreas, 2013, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult

2013
Chemoradiotherapy for locally advanced pancreatic cancer.
    The Lancet. Oncology, 2013, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms

2013
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Common Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Proton Therapy; Radiation Injuries; Radiotherapy Dosage; Retrospective Studies

2013
Radiotherapy in the management of pancreatic neuroendocrine tumors (PNET): experience at three institutions.
    Anticancer research, 2013, Volume: 33, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant

2013
Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.
    Radiation oncology (London, England), 2013, Jul-03, Volume: 8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome

2013
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution

2013
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
    JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines

2013
A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    JOP : Journal of the pancreas, 2013, Sep-10, Volume: 14, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Temozolomide; Thrombocytopenia; Time Factors; Treatment Outcome

2013
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Cutaneous and ocular toxicology, 2014, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Naphthoquinones; Pancreatic Neoplasms

2014
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms

2014
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Radiation oncology (London, England), 2013, Oct-31, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome

2013
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Annals of surgical oncology, 2014, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors

2014
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
    Cancer immunology, immunotherapy : CII, 2014, Volume: 63, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Vaccination

2014
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome

2016
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids

2014
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    The oncologist, 2014, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome

2014
Patients with advanced disease: the value of patient reported outcomes.
    Oncology research and treatment, 2014, Volume: 37, Issue:1-2

    Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Pain; Pancreatic Neoplasms; Quality of Life

2014
Are we systematically under-dosing patients with fluorouracil?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Duodenal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy

2015
Pancreatic neuroendocrine tumors: does chemotherapy work?
    JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2

    Topics: Algorithms; Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Temozolomide; Treatment Outcome

2014
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Journal of the American College of Surgeons, 2014, Volume: 219, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate

2014
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease Progression; Fatal Outcome; Fluorouracil; Genes, ras; Humans; Indoles; Male; Melanoma; Mutation; Neoplasms, Second Primary; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins; Skin Neoplasms; Sulfonamides; Vemurafenib

2014
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome

2014
Locally advanced unresectable pancreatic cancer.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome

2014
Role of neoadjuvant therapy in management of pancreatic cancer.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome

2014
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting

2014
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome

2014
Radiation recall gastritis secondary to erlotinib in a patient with pancreatic cancer.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gastritis; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries; Radiography; Thymidine Phosphorylase; Withholding Treatment

2014
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
    Medicine, 2015, Volume: 94, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Salvage Therapy

2015
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Oncology, 2015, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Treatment Outcome

2015
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
    Clinical therapeutics, 2015, Jun-01, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom

2015
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    Journal of surgical oncology, 2015, Volume: 111, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis

2015
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Journal of Korean medical science, 2015, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome

2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome

2016
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
    Medicine, 2015, Volume: 94, Issue:31

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins

2015
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcohol-Related Disorders; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Pneumonia; Retrospective Studies; Risk Factors; Severity of Illness Index; Smoking

2016
A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer.
    Anti-cancer drugs, 2016, Volume: 27, Issue:2

    Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Upper Gastrointestinal Tract

2016
Capecitabine as a Radiosensitizer in Adjuvant Chemoradiotherapy for Pancreatic Cancer: A Retrospective Study.
    Anticancer research, 2015, Volume: 35, Issue:12

    Topics: Aged; Capecitabine; Chemoradiotherapy, Adjuvant; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate

2015
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Annals of surgical oncology, 2016, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids

2016
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate

2016
Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2016, Volume: 14, Issue:3

    Topics: Administration, Oral; Ambulatory Care Facilities; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cost Savings; Costs and Cost Analysis; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Medication Errors; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Care; Patient Compliance; Patient Education as Topic; Rectal Neoplasms

2016
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX.
    Oncology, 2016, Volume: 90, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome

2016
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors.
    Endocrine-related cancer, 2016, Volume: 23, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins

2016
Pancreatic Cancer Survival Increases with Chemo Combo.
    Cancer discovery, 2016, Volume: 6, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome

2016
[Radiation therapy of pancreatic cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Neoadjuvant Therapy; Organs at Risk; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided

2016
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors.
    Endocrine-related cancer, 2016, Volume: 23, Issue:9

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co-Repressor Proteins; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Female; Humans; Male; Middle Aged; Molecular Chaperones; Neuroendocrine Tumors; Nuclear Proteins; Pancreatic Neoplasms; Telomere; Temozolomide; Treatment Outcome; Tumor Suppressor Proteins; X-linked Nuclear Protein

2016
A Case Report-Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine.
    Journal of gastrointestinal cancer, 2018, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Duodenal Neoplasms; Humans; Male; Middle Aged; Pancreatic Neoplasms; Stevens-Johnson Syndrome

2018
Ecological Factors in Human Development.
    Child development, 2017, Volume: 88, Issue:3

    Topics: Capecitabine; Deoxycytidine; Friends; Gemcitabine; Humans; Pancreatic Neoplasms; Social Identification

2017
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
    BMC cancer, 2008, Jul-08, Volume: 8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome

2008
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
    JOP : Journal of the pancreas, 2008, Jul-10, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Herbal Medicine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Plant Preparations

2008
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
    JOP : Journal of the pancreas, 2008, Nov-03, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed

2008
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
    JOP : Journal of the pancreas, 2008, Nov-03, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin

2008
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
    BMC surgery, 2009, Jan-08, Volume: 9

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Prospective Studies; Receptor, ErbB-2; Research Design; Trastuzumab

2009
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
    Singapore medical journal, 2009, Volume: 50, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome

2009
Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene.
    JOP : Journal of the pancreas, 2009, Mar-09, Volume: 10, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathy, Dilated; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Analysis; Echocardiography; Fluorouracil; Germ-Line Mutation; Humans; Male; Middle Aged; Mutation, Missense; Pancreatic Neoplasms; Polymerase Chain Reaction; Prodrugs; Pulmonary Valve Insufficiency; Thymidylate Synthase

2009
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
    International journal of radiation oncology, biology, physics, 2009, Dec-01, Volume: 75, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome

2009
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
    Oncology, 2009, Volume: 77, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult

2009
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome

2009
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
    JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome

2009
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prognosis; Survival Analysis; Thymidine Phosphorylase

2009
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome

2009
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors

2009
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome

2010
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
    International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies

2011
Erlotinib in combination with capecitabine (5'dFUR) in resistant pancreatic cancer cell lines.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Thymidine Phosphorylase; Vascular Endothelial Growth Factor A

2010
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom

2010
Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2011, Aug-01, Volume: 80, Issue:5

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Analysis

2011
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiotherapy Dosage; Survival Rate; Treatment Outcome

2010
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Anticancer research, 2010, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids

2010
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
    Cancer, 2011, Jan-15, Volume: 117, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Islet Cell; Dacarbazine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Temozolomide; Tomography, X-Ray Computed

2011
Effects of capecitabine and celecoxib in experimental pancreatic cancer.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2010, Volume: 10, Issue:5

    Topics: Animals; Capecitabine; Celecoxib; Cricetinae; Deoxycytidine; Fluorouracil; Lipid Peroxidation; Lipid Peroxides; Male; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Pyrazoles; Sulfonamides

2010
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
    Anticancer research, 2010, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult

2010
CA 19-9 level as indicator of early distant metastasis and therapeutic selection in resected pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2011, Dec-01, Volume: 81, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies

2011
Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer.
    Pancreas, 2011, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antioxidants; Capecitabine; Cricetinae; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Lipid Peroxides; Male; Melatonin; Mesocricetus; Nitrosamines; Pancreatic Neoplasms; Prodrugs

2011
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Annals of surgical oncology, 2011, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome

2011
Unity is strength: one, two, or more drugs against advanced pancreatic cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Organoplatinum Compounds; Pancreatic Neoplasms

2011
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome

2011
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
    Journal of surgical oncology, 2011, Aug-01, Volume: 104, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids

2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome

2012
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure

2012
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult

2012
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids

2012
Resected pancreatic neuroendocrine tumors: patterns of failure and disease-related outcomes with or without radiotherapy.
    International journal of radiation oncology, biology, physics, 2012, Jul-15, Volume: 83, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure

2012
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
    International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Sex Factors; Tumor Burden

2012
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.
    JOP : Journal of the pancreas, 2012, Jul-10, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Pancreatic Neoplasms; Venous Thromboembolism

2012
Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?
    JOP : Journal of the pancreas, 2012, Jul-10, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Lapatinib; Leucovorin; Oligodeoxyribonucleotides; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Thionucleotides

2012
[A case of metastatic pancreatic cancer which trastuzumab+capecitabine combination therapy was effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Trastuzumab

2012
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Radiation oncology (London, England), 2012, Sep-13, Volume: 7

    Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha

2012
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
    International journal of clinical pharmacology and therapeutics, 2013, Volume: 51, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Glycation End Products, Advanced; HMGB1 Protein; Humans; Pancreatic Neoplasms; Prospective Studies; Statistics, Nonparametric; Treatment Outcome

2013
Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma, Neuroendocrine; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Drug Eruptions; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Necrolytic Migratory Erythema; Neoplasm Staging; Pancreatic Neoplasms; Paraneoplastic Syndromes; Risk Assessment; Temozolomide; Treatment Outcome

2013
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
    Radiation oncology (London, England), 2013, Jan-31, Volume: 8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate

2013
Locally advanced acinar cell carcinoma of the pancreas successfully treated by capecitabine and concurrent radiotherapy: report of two cases.
    Pancreas, 2003, Volume: 27, Issue:1

    Topics: Adult; Capecitabine; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radionuclide Imaging

2003
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies

2004
Peripheral neuropathy associated with capecitabine.
    Anti-cancer drugs, 2004, Volume: 15, Issue:8

    Topics: Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Administration Schedule; Female; Fluorouracil; Forecasting; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prodrugs

2004
Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages.
    Immunopharmacology and immunotoxicology, 2005, Volume: 27, Issue:1

    Topics: Aged; Capecitabine; Cell Movement; Deoxycytidine; Endothelial Cells; Female; Fluorouracil; Humans; Immunohistochemistry; Macrophages; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Thymidine Phosphorylase

2005
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Analysis

2005
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
    JOP : Journal of the pancreas, 2005, Jul-08, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy; Tomography, X-Ray Computed

2005
Capecitabine-induced pancolitis.
    International journal of colorectal disease, 2007, Volume: 22, Issue:4

    Topics: Adult; Capecitabine; Colitis; Deoxycytidine; Fluorouracil; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms

2007
Capecitabine-induced multifocal leukoencephalopathy: a report of five cases.
    Neurology, 2005, Dec-13, Volume: 65, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain; Breast Neoplasms; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Metastasis; Neurotoxicity Syndromes; Pancreatic Neoplasms; Withholding Treatment

2005
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome

2003
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1

    Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Celecoxib; Colorectal Neoplasms; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Immunohistochemistry; Intestinal Mucosa; Ki-67 Antigen; Lead; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Pyrazoles; RNA, Messenger; Sulfonamides; Xenograft Model Antitumor Assays

2005
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Clinical colorectal cancer, 2006, Volume: 5, Issue:5

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms

2006
Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gastritis; Gene Expression Regulation, Neoplastic; Humans; Male; Pancreatic Neoplasms; Radiodermatitis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Phosphorylase; Tumor Necrosis Factor-alpha

2006
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
    Future oncology (London, England), 2006, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines

2006
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
    Cancer, 2006, Dec-01, Volume: 107, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms

2006
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms

2006
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome

2008
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jun-01, Volume: 25, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic

2007
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
    Cancer, 2007, Jul-01, Volume: 110, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Time Factors; Treatment Outcome

2007
Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy.
    Neuroendocrinology, 2007, Volume: 85, Issue:4

    Topics: Adenoma, Islet Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Streptozocin; Treatment Outcome

2007
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate

2007
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2008, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States

2008
Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromogranin A; Deoxycytidine; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Tomography, X-Ray Computed

2008
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate

2007
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
    JOP : Journal of the pancreas, 2007, Nov-09, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome

2007
Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:4

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Creatinine; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Leukocyte Count; Male; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Platelet Count; Radioisotopes; Receptors, Somatostatin

2008
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
    The Lancet. Oncology, 2008, Volume: 9, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis

2008
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
    JOP : Journal of the pancreas, 2008, May-08, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy

2008
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:5-6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors

2007
Pancreatic cancer.
    Integrative cancer therapies, 2008, Volume: 7, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Naturopathy; Pancreatic Neoplasms; Pastoral Care; Physical Therapy Modalities

2008